MediWound (MDWD) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings or view top-rated stocks.

4 analysts have issued 12 month target prices for MediWound's stock. Their MDWD share price forecasts range from $25.00 to $36.00. On average, they anticipate the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 166.8% from the stock's current price.
View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts.

MediWound's stock was trading at $13.49 at the beginning of the year. Since then, MDWD shares have decreased by 19.4% and is now trading at $10.87.
View the best growth stocks for 2023 here.

MediWound saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 50,800 shares, an increase of 23.6% from the August 31st total of 41,100 shares. Based on an average trading volume of 17,900 shares, the short-interest ratio is presently 2.8 days. Approximately 0.8% of the shares of the company are sold short.
View MediWound's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our MDWD earnings forecast.

MediWound Ltd. (NASDAQ:MDWD) announced its earnings results on Tuesday, August, 15th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.51. The biopharmaceutical company earned $4.77 million during the quarter, compared to the consensus estimate of $4.19 million. MediWound had a negative trailing twelve-month return on equity of 71.45% and a negative net margin of 55.53%.

MediWound's stock reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDWD stock can currently be purchased for approximately $10.87.

MediWound (NASDAQ:MDWD) has a market capitalization of $100.11 million and generates $26.50 million in revenue each year. The biopharmaceutical company earns $-19,600,000.00 in net income (profit) each year or ($2.4297) on an earnings per share basis.

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for the company is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111.